|
NR. 4/2006
|
|
|
|
|
|
|
|
|
Avastin – nowa
nadzieja w okulistyce?
Avastin – New Hope in Ophthalmology?
Agnieszka Nowosielska, Iwona
Grabska-Liberek, Katarzyna Gurdziel
Oddzia³ Kliniczny Okulistyki Centrum Medycznego Kszta³cenia
Podyplomowego
Samodzielnego Publicznego Szpitala Klinicznego im. prof. W.
Or³owskiego w Warszawie
P.o. kierownik: dr n. med. Iwona Grabska-Liberek |
|
|
|
|
|
|
|
| Summary: |
Bevacizumab (Avastin ) is
a full – length, humanized, monoclonal antibody directed
against vascular endothelial growth factor A (VEGF-A).
Bevacizumab was the first anti-VEGF drug approved by FDA
for the treatment of colorectal cancer. Intravenous
chemotherapy combined with bevacizumab has shown
promising results and has been used in many more
oncology indications now.
VEGF is considered to be the one of the major stimuli
for neovascularization and macular edema responsible for
wet AMD, diabetic retinopathy and neovascular glaucoma.
The role of VEGF in those disorders has been shown as a
result of clinical trial with anti-VEGF drug known as
pegaptanib (Macugen).
In 2004, first trial with Avastin used in the treatment
of wet AMD was launched in
Bascom Palmer Eye Institute, Miami, USA. SANA Trial (Systemic
Avastin for Neovascular AMD) has shown good results both
as far as safety and efficacy of the treatment were
concerned.
Intravitreal bevacizumab has now been given for a few
years. It has shown very promising results and it turned
out to be relatively safe when given locally. It is also
much cheaper than other approved anti-VEGF ophthalmic
therapy.
But we still do not know if it is going to be our magic
drug? |
| |
|
| Key words: |
Avastin, Bevacizumab, AMD,
diabetic retinopathy, retinal vein occlusion,
neovascular glaucoma, VEGF (vascular endothelial growth
factor). |
|
|
|
|
|
|
|
|
